Skip to main content Accessibility help
×
Home
Hostname: page-component-cf9d5c678-w9nzq Total loading time: 0.503 Render date: 2021-08-04T20:37:54.931Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

EARLY DIALOGUE WITH HEALTH TECHNOLOGY ASSESSMENT BODIES: A EUROPEAN PERSPECTIVE

Published online by Cambridge University Press:  30 March 2015

Matthieu Cuche
Affiliation:
Covidien, matthieu.cuche@covidien.com
Rachel Beckerman
Affiliation:
CBPartners, Rachel.beckerman@cbpartners.com, cyrus.chowdhury@cbpartners.com
Cyrus A. Chowdhury
Affiliation:
CBPartners, Rachel.beckerman@cbpartners.com, cyrus.chowdhury@cbpartners.com
Marije A. van Weelden
Affiliation:
Ferring, marije.vanweelden@ferring.com

Abstract

Introduction: Evidence requirements may differ across HTA bodies, and so pharmaceutical companies must plan to synergize their evidence generation strategy, across global regulatory and HTA bodies. Until recently, companies had no official platform to discuss the clinical development of a drug with HTA bodies; however, this is changing.

Objectives: To achieve broad usage in the EU, products must achieve both regulatory and reimbursement approval, the latter of which is based on HTA appraisal in many markets. The objective of this study is to present and evaluate the different options available for early HTA consultation (during drug development/Phase III) in the major European markets from the industry perspective.

Methods: An exploratory (nonsystematic) literature review was performed to identify the European markets offering early HTA consultations, and each process was analyzed using a set of predefined metrics that are relevant to industry (the ability to consult with the regulatory body in parallel, consultation fees, length of consultation meeting, language of consultation meeting, maximum number of pharmaceutical company employees attending, procedural timelines, nature of data for which consultative advice can be sought, the output of the process, and the ability to involve external experts).

Results: Four different types of early HTA consultation processes were identified across the major European HTA markets. The nature of these processes varied in terms of the types and number of questions that can be addressed, the length of the meeting, the reporting output, and the ability to involve external experts.

Conclusions: The availability of various options for early HTA consultation may help to avoid a mismatch between the evidence generated by means of a product's clinical development program, and the evidence expected by HTA bodies and payers, which can facilitate the pricing and reimbursement process upon a product's market authorization.

Type
Methods
Copyright
Copyright © Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

2. Scottish Medicines Consortium. Ipilimumab (Yervoy®) 5mg/mL concentrate for solution for infusion, SMC No. (779/12). Glasgow: Scottish Medicines Consortium; 2011.Google Scholar
3. National Institute for Clinical Excellence. Ipilimumab: Appraisal consultation. London: NICE; 2011.Google Scholar
4. National Institute for Clinical Excellence. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. London: NICE; 2012.Google ScholarPubMed
5. Scottish Medicines Consortium. Ipilimumab (Yervoy®) 5mg/mL concentrate for solution for infusion, SMC No. (779/12). Glasgow: Scottish Medicines Consortium; 2013.Google Scholar
6. Gemeinsame Bundesausschuss. Beschlusse uber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Funften Buches Sozialgesetzbuch (SGB V): Linagliptin. 2012.Google Scholar
7. Bruce, F. No hope for BI/Lilly's Trajenta in Germany, but will prescribers care? 2013. http://www.scripintelligence.com/home/No-hope-for-BILillys-Trajenta-in-Germany-but-will-prescribers-care-340249 (accessed May 9, 2013).Google Scholar
8. Beckerman, R, Chowdhury, CA. Payer prophecy: Pricing and access optimisation by trial design. 2012. CBPartners. http://www.cbpartners.com/thoughtleadership/PR%20Optimised%20Trial%20Design.pdf (accessed June 2013).Google Scholar
9. Backhouse, ME, Wonder, M, Hornby, E, et al. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health. 2011;14:608615.CrossRefGoogle ScholarPubMed
10. Silverman, E. Clinical trials costs are rising rapidly. 2011. Pharmalot. http://www.pharmalive.com/clinical-trial-costs-are-rising-rapidly (accessed May 6, 2013).Google Scholar
11. Dental and Pharmaceutical Benefits Board (TLV). Joint scientific advice meetings between the Dental and Pharmaceutical Benefits Agency (TLV) and the Medical Products Agency (MPA). 2010. http://www.lakemedelsverket.se/english/product/Medicinal-products/Scientific-advice/Pilot-project-of-joint-scientific-advice-meetings-arranged-by-the-TLV-and-the-MPA/ (accessed May 7, 2013).Google Scholar
12. Federal Joint Committee. The benefit assessment of pharmaceuticals in accordance with the German Social Code, Book Five (SGB V), section 35a. 2011. http://www.english.g-ba.de/benefitassessment/information/#9 (accessed May 7, 2013).Google Scholar
13. National Institute for Clinical Excellence. NICE scientific advice. 2012. http://www.nice.org.uk/aboutnice/scientificadvice/AboutScientificAdvice.jsp (accessed May 7, 2013).Google Scholar
14. College voor zorgverezekeringen. CVZ - Scientific Advice. 2013. http://www.cvz.nl/zorgpakket/cfhagenda/commissie/wetenschappelijk+advies/wetenschappelijk+advies.html (accessed May 7, 2013).Google Scholar
15. Pavlovic, M. Early dialogues: EUnetHTA JA2 WP7. 2012. http://www.topra.org/sites/default/files/assets/pdf/pavlovic.pdf (accessed May 7, 2013).Google Scholar
16. EUnetHTA. Final minutes of EMA/EUnetHTA meeting. 2013. EUnetHTA. http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/EUnetHTA-EMA%20f-t-f%20meeting%20summary%2020130514%20London%20UK.pdf (accessed June 14, 2013).Google Scholar
17. Moseley, J. HTA-EMA scientific advice. 2012. Presented at the TOPRA Annual 2012 Symposium. Dublin, Ireland. October 1, 2012.Google Scholar
18. Tapestry Networks. Pilots of multi-stakeholder consultations in drug development. 2012. http://www.tapestrynetworks.com/initiatives/healthcare/upload/Pilots-of-multi-stakeholder-consultations-in-drug-development-6-June-2012.pdf (accessed June 4, 2013).Google Scholar
19. Hutton, J, Trueman, P, Facey, K. Harmonization of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care. 2008;24:511517.CrossRefGoogle ScholarPubMed
20. Wonder, M, Backhouse, ME, Hornby, E. Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia. Value Health. 2013;16:10671073.CrossRefGoogle Scholar
Supplementary material: File

Cuche supplementary material

Figure S1

Download Cuche supplementary material(File)
File 65 KB
4
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

EARLY DIALOGUE WITH HEALTH TECHNOLOGY ASSESSMENT BODIES: A EUROPEAN PERSPECTIVE
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

EARLY DIALOGUE WITH HEALTH TECHNOLOGY ASSESSMENT BODIES: A EUROPEAN PERSPECTIVE
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

EARLY DIALOGUE WITH HEALTH TECHNOLOGY ASSESSMENT BODIES: A EUROPEAN PERSPECTIVE
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *